

**Form 51-102F3**  
***Material Change Report***

**Item 1      Name and Address of Company**

Mydecine Innovations Group Inc. (the “Company”)  
Suite 810 - 789 West Pender Street  
Vancouver, BC V6C 1H2

**Item 2      Date of Material Change**

September 7, 2022

**Item 3      News Release**

A news release was disseminated on September 14, 2022 through the facilities of Cision Newswire and subsequently filed on the SEDAR

**Item 4      Summary of Material Change**

In connection with its previously announced Common Share Subscription Agreement (the “Subscription Agreement”) with a third-party investor (the “Investor”) dated August 26, 2022, the Company has filed a shelf prospectus supplement (the “Prospectus Supplement”) in connection therewith on September 7, 2022. The Company also announced that it has closed the first tranche (the “Offering”) under the Subscription Agreement.

**Item 5      Full Description of Material Change**

**5.1      Full Description of Material Change**

The Prospectus Supplement is the first supplement filed in connection with the Subscription Agreement and provides, among other things, that the Company is qualifying the distribution of up to 1,754,386 common shares (each a “Share”) in the capital of the Company to the Investor at a price of \$0.57 per Share for aggregate gross proceeds of up to \$1,000,000.

The Offering resulted in the issuance of 877,193 Shares at a price of \$0.57 per Share for aggregate gross proceeds of \$500,000. The distribution of such Shares is qualified by the Prospectus Supplement.

**5.2      Disclosure for Restructuring Transactions**

Not applicable.

**Item 6      Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7      Omitted Information**

Not applicable.

**Item 8      Executive Officer**

David Joshua Bartch,  
Chief Executive Officer  
604-687-2038  
jbartch@mydecineinc.com

**Item 9      Date of Report**

September 20, 2022